Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent tamibarotene: Characterization and evaluation

Drug Delivery

Volumn 22, Issue 2, 2015, Pages 223-229

  Liu, Xin ^a   Zhang, Zhihua ^a   Jiang, Yuqi ^a   Hu, Yue ^a   Wang, Zhonglan ^a   Liu, Junli ^a   Feng, Ruihua ^a   Zhang, Jie ^a   Huang, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Biodistribution; Intravenous delivery; Nanostructured lipid carrier; PEGylated; Pharmacokinetic; Tamibarotene

Indexed keywords

DRUG CARRIER; MACROGOL; MACROGOL 40 STEARATE; PEGYLATED NANOSTRUCTURED LIPID CARRIER; STEARIC ACID; TAMIBAROTENE; TAMIBAROTENE LOADED NANOSTRUCTURED LIPID CARRIER; TAMIBAROTENE LOADED PEGYLATED NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; MACROGOL DERIVATIVE; NANOMATERIAL; PEG 40 MONOSTEARATE; PHOSPHATIDYLCHOLINE; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ENTRAPMENT EFFICIENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EMULSION; FEMALE; LOW TEMPERATURE PROCEDURES; LOW TEMPERATURE SOLIDIFICATION; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RAT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LEUKEMIA, PROMYELOCYTIC, ACUTE; METABOLISM; OUTBRED STRAIN; RANDOMIZATION; SOLUBILITY; SURFACE PROPERTY; TISSUE DISTRIBUTION; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTINEOPLASTIC AGENTS; BENZOATES; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; LECITHINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; NANOSTRUCTURES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; RATS, WISTAR; SOLUBILITY; SURFACE PROPERTIES; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION;

EID: 84921630467     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.885614     Document Type: Article

References (32)

1. Beletsi A, Panagi Z, Avgoustakis K. (2005). Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm 298:233-41.
2. Gref R, Domb A, Quellec P, et al. (1995). The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215-32.
3. Harris JM, Martin NE, Modi M. (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-51.
4. Jia L, Shen J, Zhang D, et al. (2012). In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol 50:523-9.
5. Jia L, Zhang D, Li Z, et al. (2010). Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 80:213-8.
6. Joshi MD, Müller RH. (2009). Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161-72.
7. Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97-109.
8. Kawahara K, Nishi K, Suenobu M, et al. (2009). Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain b-amyloid peptides in APP23 Mice. Biol Pharm Bull 32:1307-9.
9. Kim HK, Davaa E, Myung CS, Park JS. (2010). Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 392:141-7.
10. Kimura Y, Oyashiki K. (2005). Evaluation of the new drug by the clinician. Tamibarotene. Clin Pract 24:991-3.
11. Lipka J, Semmler-Behnke M, Sperling RA, et al. (2010). Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31:6574-81.
12. Liu D, Liu Z, Wang L, et al. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262-9.
13. Liu D, Wang L, Liu Z, et al. (2010). Preparation, characterization, and in vitro evaluation of docetaxel-loaded poly (lactic acid)-poly (ethyleneglycol) nanoparticles for parenteral drug delivery. J Biomed Nanotechnol 6:675-82.
14. Liu X, Wang Z, Feng R, et al. (2013). A novel approach for systematic delivery of a hydrophobic anti-leukemia agent Tamibarotene mediated by nanostructured lipid carrier. J Biomed Nanotechnol 9:1586-93.
15. Luo Q, Zhao J, Zhang X, Pan W. (2011). Nanostructured lipid carrier (NLC) coated with Chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185-91.
16. Malugin A, Ghandehari H. (2010). Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol 30:212-7.
17. Miwako I, Kagechika H. (2007). Tamibarotene. Drugs Today (Barc) 43:563-8.
18. Ohnishi K. (2007). PML-RARa inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 12:313-7.
19. Oikawa T, Okayasu I, Ashino H, et al. (1993). Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol 249:113-6.
20. Shen J, Wang Y, Ping Q, et al. (2009). Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 137:217-23.
21. Shudo K, Kagechika H, Yamazaki N, et al. (2004). A synthetic retinoid Am80 (Tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. Biol Pharm Bull 27:1887-9.
22. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16:195-214.
23. Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31-48.
24. Sugitani M, Abe R, Ikarashi N, et al. (2009). Disposition of a new tamibarotene prodrug in mice. Biol Pharm Bull 32:1997-2001.
25. Su Z, Niu J, Xiao Y, et al. (2011). Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 8:1641-51.
26. Takeuchi M, Yano T, Omoto E, et al. (1997). Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. Br J Haematol 97:137-40.
27. Tobita T, Takeshita A, Kitamura K, et al. (1997). Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967-73.
28. Xu X, Zhao C, Yang H, et al. (2011). Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv 18:485-92.
29. Yang X, Li Y, Li M, et al. (2012). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338-45.
30. Yuan H, Wang L, Du Y, et al. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces 60:174-9.
31. Zhang T, Chen J, Zhang Y, et al. (2011). Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 43:174-9.
32. Zhang X, Pan W, Gan L, et al. (2008). Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem Pharm Bull 56:1645-50.